Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;31(12):1321-1329.
doi: 10.1111/iju.15588. Epub 2024 Sep 24.

Genitourinary malignancies in kidney transplant recipients

Affiliations
Review

Genitourinary malignancies in kidney transplant recipients

Masayoshi Okumi et al. Int J Urol. 2024 Dec.

Abstract

Advances in immunosuppressive therapy and postoperative management have greatly improved the graft and patient survival rates after kidney transplantation; however, the incidence of post-transplant malignant tumors is increasing. Post-renal transplantation malignant tumors are associated with renal failure, immunosuppression, and viral infections. Moreover, the risk of developing cancer is higher in kidney transplant recipients than in the general population, and the tendency to develop cancer is affected by the background and environment of each patient. Recently, cancer after kidney transplantation has become the leading cause of death in Japan. Owing to the aggressive nature and poor prognosis of genitourinary malignancies, it is crucial to understand their epidemiology, risk factors, and best practices in kidney transplant recipients. This review has a special emphasis on the epidemiology, risk factors, and treatment protocols of genitourinary malignancies in kidney transplant recipients to enhance our understanding of the appropriate management strategies. Optimal immunosuppressive therapy and cancer management for these patients remain controversial, but adherence to the general guidelines is recommended.

Keywords: genitourinary malignancy; immunosuppression; kidney transplantation.

PubMed Disclaimer

Similar articles

Cited by

References

REFERENCES

    1. Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, et al. Kidney transplantation as primary therapy for end‐stage renal disease: a National Kidney Foundation/kidney disease outcomes quality initiative (NKF/KDOQITM) conference. Clin J Am Soc Nephrol. 2008;3:471–480.
    1. Loupy A, Lefaucheur C, Vernerey D, Prugger C, van Huyen JPD, Mooney N, et al. Complement‐binding anti‐HLA antibodies and kidney‐allograft survival. N Engl J Med. 2013;369:1215–1226.
    1. Gill JS, Abichandani R, Kausz AT, Pereira BJ. Mortality after kidney transplant failure: the impact of non‐immunologic factors. Kidney Int. 2002;62:1875–1883.
    1. Farrugia D, Mahboob S, Cheshire J, Begaj I, Khosla S, Ray D, et al. Malignancy‐related mortality following kidney transplantation is common. Kidney Int. 2014;85:1395–1403.
    1. Lim WH, Badve SV, Wong G. Long‐term allograft and patient outcomes of kidney transplant recipients with and without incident cancer—a population cohort study. Oncotarget. 2017;8:77771–77782.

MeSH terms

Substances

LinkOut - more resources